20|0|Public
5000|$|Propionic acid {{derivatives}} (NSAIDs) - naproxen, diflunisal, ketoprofen, <b>oxaprozin,</b> mefenamic acid, rofecoxib ...|$|E
5000|$|Advantage Dose LLC {{recalled}} <b>oxaprozin</b> tablets on November 26, 2008. The {{company was}} not in conformance with cGMP. (Recall #D-837-2009) ...|$|E
50|$|<b>Oxaprozin</b> was {{developed}} and patented by Wyeth-Ayerst. The US patent 3578671, Oxazoles, was filed November 6, 1967 and published May 11, 1971. Following the filing of the patent, the first description of <b>oxaprozin</b> exhibiting anti-inflammatory properties was outlined in the article Diaryloxazole and diaylthiazolealkanoci acids: two novel series of non-steroidal anti-inflammatory agents. This article was published in Nature in 1968. In December 1988, Wyeth-Ayerst licensed the marketing rights for the US, Canada, Puerto Rico, and the Caribbean to Searle.|$|E
50|$|In {{order to}} {{evaluate}} the effectiveness of Daypro for the signs and symptoms of osteoarthritis, 616 patients participated in active controlled clinical trials against aspirin, piroxicam, and other NSAIDs. Similar to the rheumatoid arthritis clinical trials, patients were given Daypro in both variable and in fixed dosing schedules. Patients received Daypro in either single or divided doses. The variable dosing schedule ranged from 600 to 1200 mg/day and the fixed dosing schedule was set to 1200 mg/day. <b>Oxaprozin</b> was found to be comparable to 2600 to 3200 mg/day doses of aspirin or 20 mg/day doses of piroxicam. The once a day and divided dosing schedules were both effective. Several days of administration were needed for <b>oxaprozin</b> to reach its full effect.|$|E
50|$|Since the {{approval}} of Daypro by Searle, other companies have submitted abbreviated new drug applications (ANDAs) to the FDA. Daypro by Searle is listed as the Reference Listed Drug to prove the bioequivalence of the ANDAs. Below is a table listing all of the approved <b>oxaprozin</b> products.|$|E
50|$|The <b>oxaprozin</b> {{new drug}} {{application}} (NDA 18-841) was submitted to the FDA on August 10, 1982. The drug was granted an “NDA Day” review on June 15-16, 1992. After Searle agreed to complete seven Phase IV postmarketing studies on October 22, the FDA approved Daypro on October 29, 1992.|$|E
50|$|Clinical trials {{essential}} to the approval to DAYPRO involved 646 patients. The studies were intended to measure the effect of DAYPRO {{in regards to the}} signs and symptoms of rheumatoid arthritis in placebo and active controlled groups. The patients were given single or multiple doses equally 600 to 1800 mg/day. DAYPRO was found to be comparable to 2600 to 3900 mg/day of aspirin. <b>Oxaprozin</b> proved to be more effective and cause fewer adverse reactions than aspirin.|$|E
50|$|In 2015, <b>oxaprozin</b> was one {{of twenty}} NSAIDs {{included}} in a clinical trial to compare the efficacy of NSAIDs in the short-term treatment of ankylosing spondylitis (AS). The NSAIDs were compared by completing randomized controlled trials of NSAIDs in patients with active AS. Efficacy reported at 2-12 weeks and adverse effects were examined. Efficacy was measured by change in pain score and change in the duration of morning stiffness. A total of 26 trials {{with a total of}} 3410 participants were completed (58% of the trials had fewer than 50 participants). While all 20 NSAIDs were found to reduce more pain than the placebo, 15 were found to be significantly better. In regards to the decrease of morning stiffness and the likelihood of adverse events, {{there was no significant difference}} between NSAIDs. It was concluded that etoricoxib was more effective in reducing pain of AS, however due to small studies and insufficient evidence, no one NSAID could be determined to be the most effective treatment of AS. After etoricoxib, patients taking <b>oxaprozin</b> experienced the least amount of pain with fewer adverse effects than naproxen.|$|E
50|$|<b>Oxaprozin,</b> {{also known}} as Oxaprozinum, (sold under the names: Daypro, Dayrun, Duraprox) is a nonsteroidal {{anti-inflammatory}} drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. It is available in 600 mg tablets. Normal adult dosage is 1200 mg daily, not to exceed 1800 mg per day. Safety and efficacy {{has been established in}} children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.|$|E
40|$|A {{series of}} 42 healthy {{male and female}} volunteers aged 21 to 89 years {{received}} a single 1200 mg oral dose of <b>oxaprozin.</b> Kinetics were determined from multiple plasma <b>oxaprozin</b> concentrations measured by h. p. l. c. during 14 days after the dose. Peak plasma <b>oxaprozin</b> concentrations were reached between 3 and 6 h after dosage the majority of subjects, probably reflecting slow absorption from the gastrointestinal tract. Elimination also was slow with a mean half-life of 59 h (range 36 to 92 h). Owing in part to extensive protein binding (mean free fraction 0. 0023 %), <b>oxaprozin</b> distribution was limited, with apparent volume of distribution averaging 0. 25 l/kg. Apparent volume of distribution declined with increasing age, probably reflecting the reduction in lean mass relative to total weight that occurs in the elderly. Total apparent <b>oxaprozin</b> clearance declined with age in men (r = - 0. 58, P less than 0. 01), but was not significantly related to age in women (r = - 0. 25, NS). This {{is consistent with the}} previously described gender-specific reduction in hepatic oxidizing capacity association with increasing age. Thus <b>oxaprozin</b> is a slowly eliminated nonsteroidal anti-inflammatory agent that should be suitable for once daily or every other day administration...|$|E
40|$|<b>Oxaprozin</b> (3 -(4, 5 -difeniloksazol- 2 -yl) propanoic acid) is a nonsteroidal {{anti-inflammatory}} drug (NSAID) used in {{the treatment}} of numerous inflammatory musculoskeletal diseases, including rheumatoid arthritis, osteoarthritis, tendonitis, ankylosing spondylitis and bursitis. It is the first representative member of the diaryl-substituted heterocyclic compounds, which have found clinical use as selective cyclooxygenase- 2 (COX- 2) inhibitors. U. S. Food and Drug Administration (FDA) approved its official use in 1992. Both anti-inflammatory and analgesic properties of <b>oxaprozin</b> are mainly due to the potent inhibition of COX. However, oxaprozin-induced benefits might be also regulated by other COX-independent pathways. It has been shown that <b>oxaprozin</b> induced direct proapoptotic effects in CD 40 L-treated human monocytes independently of COX inhibition. It also has several advantages {{in the treatment of}} inflammatory diseases in comparison to other NSAIDs such as aspirin, naproxen, indomethacin and phenylbutazone, which enabled <b>oxaprozin</b> {{to become one of the}} most used NSAIDs in America. <b>Oxaprozin,</b> as other members of the group of NSAIDs, can cause gastrointestinal complications, but significantly lower due to relatively high pKa value. In this paper, importance of <b>oxaprozin</b> in the treatment of arthritis and its pharmacokinetic properties were described, therewith its activity and side effects were compared with other commercially available anti-inflammatory drugs...|$|E
40|$|Immunoassay {{methods are}} {{commonly}} used to screen for drugs of abuse and some prescription drug classes as part of drug-testing programs in clinical and forensic toxicology. <b>Oxaprozin</b> (Daypro | is a new nonsteroidal anti-inflammatory d ug that is widely prescribed in North America and {{has been reported to}} cross-react for benzodiazepines in several different immunoassay methods. The first objective {{of this study was to}} characterize the immunoreactivity of <b>oxaprozin</b> standards over a wide concentration range when analyzed by the EMIT dau, Abbott FPIA, and BMC CEDIA urine henzodiazepine assays. The second objective was to measure the immunoreactivity of urine specimens obtained from 12 subiects after receiving a single oral dose (1200 mg) of <b>oxaprozin.</b> Urine <b>oxaprozin</b> standards were prepared in drug-free urine at seven concentrations ranging from 500 to 100, 000 ng/mL. The standards gave presumptive positive benzodiazepine results between 5000 and 10, 000 ng/mL (EMIT dau) and approximately 10, 000 ng/mL (FPIA, CEDIA). With a 200 -ng/mL cutoff for benzodiazepines in lhege assays, all 36 urine specimens collected from the 12 subjects gave positive results by EMIT and CEDIA, and 35 of 36 urine specimens were positive by FPIA. It was concluded that presumptive positive benzodiazepine results by these immunoassays may be due to the presence of <b>oxaprozin</b> or <b>oxaprozin</b> metabolites. It is recommended that all positive immunoassay screening tests for benzodiazepines be confirmed by another technique based upon a different pri ciple of analysis...|$|E
40|$|CASESUMMARY: A 56 -year-old {{woman was}} {{admitted}} with fulminant hepatic failure. Work-up for potential etiologies was negative {{except for the}} use of <b>oxaprozin</b> for the preceding two months. Results of premortem liver biopsy were consistent with drug-induced hepatic injury similar to that previously reported with diclofenac. DISCUSSION: Although the literature describes elevation in hepatic transaminase concentrations associated with <b>oxaprozin,</b> fulminant hepatic failure has not been described previously. CONCLUSIONS: Elevations in hepatic transaminase concentrations and now fulminant hepatic failure have been shown to occur with <b>oxaprozin,</b> as previously seen with other nonsteroidal antiinflammatory drugs (NSAIDs). Transaminitis is a known adverse effect of NSAID use, but is usually mild and reversible with discontinuation of drug. Transaminitis {{may be more likely to}} occur in the elderly, in patients receiving concurrent potentiall...|$|E
40|$|As {{the very}} first {{electrochemical}} investigation of <b>oxaprozin,</b> nonsteroidal anti-inflammatory drug, using cyclic voltammetry on gold electrode in 0. 05 mol dm- 3 NaHCO 3, the synthesized drug, its analytical standard and its content in Duraprox ® tablets were characterized with one oxidation reaction and the three reduction reactions. All they exhibited the linear concentration dependency of anodic currents at 0. 83 V for the analytical standard and 0. 85 V for Duraprox ® tablets {{in the range of}} concentrations 8. 44 – 32. 78 × 10 - 6 mol dm- 3. The strong adsorption of bovine serum albumin (BSA) on gold electrode in 0. 1 mol dm- 3 phosphate buffer solution (pH 7. 4) is shown and concentration dependency of anodic currents of <b>oxaprozin</b> standard on BSA / Au is studied. Following the Langmuir adsorption thermodynamic equation, the binding constants of <b>oxaprozin</b> on BSA / Au electrode was calculated with the results 1. 23 × 105 dm 3 mol- 1...|$|E
40|$|Analytical {{interferences}} periodically {{occur when}} testing for drugs of abuse in urine and are widely reported (1 - 7). Immunoassays are particularly prone {{to these problems}} since an extraction step is not required and, often, the antibodies used as reagents show cross-reactivity with more than the drug of interest or its metabolites (2 - 5). Recently we detected false-positive benzodiazepine re-sults when testing urine samples from a patient receiving a once-daily 1200 -mg dose of <b>oxaprozin</b> (4, 5 -diphenyl- 2 -ox-azolepropionic acid, Dayprotm; G. D. Searle, Chicago, IL). <b>Oxaprozin</b> is a nonsteroidal antiinflammatory drug ap-proved in 1993 by the US Food and Drug Administration for once-daily treatment of rheumatoid arthritis and os-teoarthritis. Taken orally, the drug is well absorbed, achieving a peak plasma concentration in 3 - 6 h. Oxaprozi...|$|E
40|$|BACKGROUND AND PURPOSE:Non-steroidal {{anti-inflammatory}} drugs (NSAIDs) {{have been}} shown to induce PG-independent anti-inflammatory actions. Here, we investigated the role of three different NSAIDs (naproxen, ibuprofen and <b>oxaprozin)</b> on neutrophil responses to CXCL 8 and C 5 a. EXPERIMENTAL APPROACH:Human neutrophils were isolated from healthy volunteers by dextran and Ficoll-Hypaque density gradients. Neutrophils were pre-incubated with different concentrations (1 - 100 µM) of NSAIDs or kinase inhibitors. Neutrophil degranulation into supernatants was tested by elisa and zymography. Neutrophil chemotaxis was determined using Boyden chambers. F-actin polymerization was determined by Alexa-Fluor 488 -conjugated phalloidin fluorescent assay. Integrin expression was assessed by flow cytometry. The phosphorylation of intracellular kinases was studied by Western blot. KEY RESULTS:Pretreatment with NSAIDs did not affect neutrophil degranulation, but inhibited neutrophil migration and polymerization of F-actin, in response to CXCL 8 and C 5 a. Pretreatment with different NSAIDs prevented C 5 a-induced integrin (CD 11 b) up-regulation, while only ibuprofen reduced CXCL 8 -induced CD 11 b up-regulation. Pre-incubation with naproxen or <b>oxaprozin,</b> but not ibuprofen, inhibited the PI 3 K/Akt-dependent chemotactic pathways. Both endogenous (released in cell supernatants) or exogenous (added to cell cultures) PGE 2 did not affect C 5 a- or CXCL 8 -induced activities. Short-term incubation with NSAIDs did not affect neutrophil PGE 2 release. CONCLUSION AND IMPLICATIONS:Treatment with NSAIDs reduced C 5 a- and CXCL 8 -induced neutrophil migration and F-actin polymerization via different mechanisms. Inhibition by ibuprofen was associated with integrin down-regulation, while naproxen and <b>oxaprozin</b> blocked the PI 3 K/Akt pathway. Both NSAID actions were independent of COX inhibition and PGE 2 release...|$|E
40|$|The {{modulation}} of CD 40 L activity might {{represent a}} promising therapeutic target to reduce monocyte inflammatory functions in chronic diseases, such as rheumatoid arthritis. In the present study, we investigated the possible influence of nonsteroidal anti-inflammatory drugs (NSAIDs) on CD 40 L-induced monocyte survival. Monocytes were isolated from buffy coats by using Ficoll-Percoll gradients. Monocyte apoptosis was evaluated by fluorescence microscopy on cytopreps stained with acridine orange or using flow cytometry analysis of Annexin-V and Propidium Iodide staining. Akt and NF-&#x 03 BA;B activation {{was assessed using}} western blot. Caspase 3 activity was determined spectrophotometrically. Among different NSAIDs, only <b>oxaprozin</b> dose-dependently increased apoptosis of CD 40 L-treated monocytes. <b>Oxaprozin</b> pro-apoptotic activity {{was associated with the}} inhibition of CD 40 L-triggered Akt and NF-&#x 03 BA;B phosphorylation and the activation of caspase 3. In conclusion, our data suggest that oxaprozin-induced apoptosis in CD 40 L-treated human monocytes is associated with previously unknown cyclooxygenase (COX) -independent pathways. These intracellular proteins might be promising pharmacological targets to increase apoptosis in CD 40 L-treated monocytes...|$|E
40|$|A {{simple and}} {{sensitive}} extractive spectrophometric method {{has been described}} for the assay of <b>oxaprozin</b> (OXA) either in pure form or in pharmaceutical solid dosage form. The developed method involves formation of colored chloroform extractable ion-pair complex of OXA with bromocresol green in aqueous acidic medium. The extracted complexes showed absorbance maxima at 421 nm. Beer's law is obeyed in the concentration range of 10 - 50 μg mL- 1. This method {{has been applied to}} the determination of drug in commercial tablets. Results of analysis were validated statistically. The excipients present in the formulations do not interfere with the assay procedure...|$|E
40|$|Nonsteroidal {{anti-inflammatory}} drugs (NSAIDs) {{have been}} re-ported to induce apoptosis {{in a variety}} of cell lines. In this study, we examined the effect of NSAIDs on the growth and apoptosis of synovial cells from patients with rheumatoid arthritis and analyzed the activation of peroxisome proliferator-activated re-ceptor (PPAR) as a possible mechanism of action of NSAIDs. Cell proliferation and viability were assessed from 5 -bromo- 2 -deoxyuridine incorporation and by 4 -[3 -(4 -iodophenyl) - 2 -(4 -nitro-phenyl) - 2 H- 5 -tetrazolio]- 1, 3 -benzene disulfonate (WST- 1) assay, respectively. The apoptosis of synovial cells was identified by DNA fragmentation assay and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay. Indometacin, diclofenac, <b>oxaprozin,</b> and zaltoprofen reduced cell proliferation and induced apoptotic cell death in synovial cells, whereas ketoprofen an...|$|E
40|$|Although {{progress}} has been made in the clinical metrology of pain in osteoarthritis, much further work remains. The preferred methods of measurement remain debatable. In this longitudinal, open study, a comparison of eight self-rating pain scales has been conducted. A total of 333 patients entered the four-week study after completing a 3 - 7 day NSAID-free washout period. Patients were assigned to treatment with <b>oxaprozin</b> 1200 mg p. o. once daily with titration permitted between 600 mg and 1800 mg. Rescue analgesia with acetaminophen (paracetamol) 325 mg (maximum 2600 mg) was allowed. At the end of the washout and the treatment period, patients completed eight self-administered pain scales. All pain measures detected clinically important and statistically significant improvements in pain. The pain scales differed in their degree of responsiveness. The Likert and visual analogue scales and their primary variations (continuous chromatic analogue and numerical scales) were more responsive than more complex measures. A positive correlation between initial pain rating and subsequent pain relief was confirmed in this study. We conclude that, while pain is a subjective sensory phenonmenon, its perceived severity can be evaluated using a variety of self-administered pain scales, all of which are capable of detecting improvements in health status following effective pharmacological intervention...|$|E

